CTNNB1 mutations and beta-catenin expression in endometrial carcinomas

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Mutations in the beta-catenin gene (CTNNB1) and abnormal nuclear beta-catenin accumulation are observed in endometrial carcinoma (EC).
• The association between CTNNB1 mutations and microsatellite instability (MI) in EC is not well understood.
• Matrix metalloproteinase-7 (MMP-7) and cyclin D1 (cD) are proposed targets of beta-catenin activation.

Purpose of the Study:

• To investigate the relationship between CTNNB1 mutations and microsatellite instability (MI) in endometrial carcinoma (EC).
• To explore the potential role of MMP-7 and cyclin D1 (cD) as targets of beta-catenin activation in EC.

Main Methods:

• DNA analysis of 73 EC patients (tumor and normal tissue) using single-strand conformation polymorphism and DNA sequencing to detect CTNNB1 mutations.
• Microsatellite instability (MI) analysis using established markers (BAT 25, BAT 26, (CA)n repeats).
• Immunohistochemical analysis of beta-catenin, MMP-7, and cD expression in EC tissues.

Main Results:

• CTNNB1 mutations were found in 15 of 73 ECs (20.5%), exclusively in endometrioid carcinomas (15/59, 25.4%).
• CTNNB1 mutations occurred in both MI-positive (6/19, 31.5%) and MI-negative (9/54, 16.6%) ECs.
• Nuclear beta-catenin immunostaining was significantly associated with CTNNB1 mutations (11/15 cases, P <.05).
• Significant expression of cyclin D1 (cD) was observed in 8 ECs, with 5 (62.5%) exhibiting CTNNB1 mutations (P <.05).
• MMP-7 expression was observed in 23 ECs, with 7 (30.4%) showing CTNNB1 mutations.

Conclusions:

• Beta-catenin plays a significant role in endometrial carcinogenesis, particularly in endometrioid subtypes.
• The findings suggest that MMP-7 and especially cyclin D1 (cD) may be downstream targets of beta-catenin activation in EC.